Dr. Martin E Gutierrez
Claim this profileJohn Theurer Cancer Center at Hackensack University Medical Center
Expert in Cancer
Expert in Solid Tumors
48 reported clinical trials
85 drugs studied
About Martin E Gutierrez
Education:
- Obtained MD from the University of Texas Southwestern Medical School, Dallas, TX.
Experience:
- Completed Residency in Internal Medicine at the University of Texas Southwestern Medical Center, Dallas, TX.
- Undertook Fellowship in Hematology and Oncology at the same institution.
- Serving as an attending physician at the John Theurer Cancer Center at Hackensack University Medical Center, with a specialization in hematology and oncology.
Area of expertise
1Cancer
Global LeaderStage IV
Stage III
KRAS positive
2Solid Tumors
Global LeaderStage IV
Stage III
KRAS positive
Affiliated Hospitals
Clinical Trials Martin E Gutierrez is currently running
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This clinical trial plans to assess to what extent the on-treatment circulating tumor DNA (ctDNA) can predict the subset of patients with NSCLC who will respond to immunotherapy treatment only and which patients will need both immunotherapy and chemotherapy modalities for their treatment regimen.
Recruiting1 award Phase 219 criteria
Atezolizumab + Bevacizumab
for Gastrointestinal Cancer
This study is a non-randomized, open-label, multi-cohort, multi-site, pilot feasibility therapeutic trial. The study will enroll 20 patients across 4 cohorts (CRC, gastric, PDAC, and HCC/intra-hepatic-/extra-hepatic-, gall bladder adenocarcinomas) diagnosed with histologically confirmed GI cancers. These patients will have already completed all Standard of Care (SOC) treatments (including neoadjuvant, surgery, local therapies, and/or adjuvant therapy as applicable), as defined by the treating primary physician or research team, with curative intent but have a positive SignateraTM tumor-informed ctDNA test and NED radiographically by standard imaging within 28 days prior to enrollment and within 1 year of completing all curative-intent therapy. All patients will be treated with intravenous (IV) atezolizumab 1200 mg IV and bevacizumab 15 mg/kg on Day 1 of 21-day cycles until disease recurrence, ctDNA POD, unacceptable toxicity, or subject withdrawal of consent with a maximum 12 month total duration of study therapy. Atezolizumab and bevacizumab drug will be provided.
Recruiting2 awards Phase 3
More about Martin E Gutierrez
Clinical Trial Related3 years of experience running clinical trials · Led 48 trials as a Principal Investigator · 18 Active Clinical TrialsTreatments Martin E Gutierrez has experience with
- Nivolumab
- Pembrolizumab
- Ipilimumab
- Carboplatin
- Docetaxel
- Atezolizumab
Breakdown of trials Martin E Gutierrez has run
Cancer
Solid Tumors
Lung Cancer
Non-Small Cell Lung Cancer
Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Martin E Gutierrez specialize in?
Is Martin E Gutierrez currently recruiting for clinical trials?
Are there any treatments that Martin E Gutierrez has studied deeply?
What is the best way to schedule an appointment with Martin E Gutierrez?
What is the office address of Martin E Gutierrez?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.